Newsroom

Publications

New Scientific Publication

We are pleased to announce our newest paper in Cancers MDPI is now published online! This work unveils the potential of Apmonia Therapeutics’ lead candidate TAX2 (AP-01)

READ MORE »
Publications

New Scientific Publication

Apmonia Therapeutics’ lead program (AP-01 or TAX2) is a cyclic peptide targeting TSP-1 (a ligand of CD47 receptor) across various tumor indications with high unmet

READ MORE »